A. Plumbe

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Sarah F. Griffee, Susan M. Kilroy, Philip Smith, 2022, The Lancet Gastroenterology & Hepatology.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Susan M. Kilroy, C. Lees, T. Ahmad, 2022, Nature Communications.

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

J. Graggaber, G. Boehmer, G. Koduri, 2023, The Lancet. Respiratory medicine.